Biotechnology Industry · global
ADARx Raises $513 Million in IPO to Advance Clinical Development of Gene-Silencing Therapies
From complement-related kidney diseases to hereditary angioedema, ADARx aims to use siRNA to reduce the production of disease-causing proteins. The IPO provides resources for multiple trials, while efficacy and long-term safety remain questions for clinical results to answer.
Getting cells to produce fewer disease-causing proteins is the core idea behind small interfering RNA (siRNA) therapies; bringing that idea to patients requires sustained investment in clinical trials. Following its initial public offering, U.S. biotechnology company ADARx Pharmaceuticals completed the underwriters’ exercise of their overallotment option on October 1, 2026, bringing total gross IPO proceeds to approximately $513.2 million and providing development resources for multiple therapeutic candidates.
This fundraising outcome differs from the filing stage in early September. At the time, Renaissance Capital reported that the company had filed for a $100 million IPO; ADARx’s S-1 filing submitted on September 4 did not yet specify the number of shares to be offered or a price range, disclosing only an application to list on Nasdaq under the ticker ADRX. The offering price was subsequently set at $17 per share, with approximately 30.19 million shares sold, including the overallotment option; the $513.2 million figure is before underwriting discounts, commissions, and offering expenses.
Additional funding came from a concurrent private placement involving AbbVie. According to ADARx’s announcement, including that investment, the IPO and private placement generated combined gross proceeds of approximately $602.5 million. This expands the company’s financial capacity to invest in research and development, but the size of the fundraising alone cannot establish the clinical value of its drug candidates.
siRNA works by recognizing specific messenger RNA and prompting cells to break it down, thereby reducing production of the corresponding protein without permanently altering DNA. ADARx’s agazisiran targets complement factor B in an effort to inhibit the alternative complement pathway; the company plans to use the funds to develop treatments for complement-related diseases, including IgA nephropathy. This pathway contributes to immune defense and can also cause tissue damage when dysregulated, so both therapeutic effects and safety risks, such as infections, require clinical validation.
According to the initial IPO filing, other uses of the proceeds include completing the Phase 3 STOP-HAE trial of onvuzosiran for hereditary angioedema, advancing ADX-626, which targets coagulation factor XI, and initiating early human trials of ADX-077 and ADX-199. This allocation spans late-stage clinical development and first-in-human studies, also meaning that the programs have varying distances to go before obtaining sufficient evidence of efficacy.
For readers, the next key question is whether the funding can translate into reliable trial results. Reducing a target protein or inhibiting a biological pathway is only one piece of evidence that a drug is exerting an effect; whether it can reduce disease attacks, protect organ function, and remain safe after repeated dosing still requires confirmation through controlled trials and long-term follow-up for each indication.